premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Sep 27/22, Up 27.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MET has achieved its target at $77. To remain disciplined, we recommend covering half the position and trailing up the stop loss (from $62) to $67. If triggered, this would result in a net investment gain of 18%.
insurance
HOLD
Switch from Canadian insurers to MET? Hit a new high today. Likes it. Financials are at a historical discount. Likes banks, insurers and diversified financials. He wouldn't switch, as some Canadian valuations are quite cheap. Nice dividend of 2.6%.
insurance
HOLD
Model price of $87.26, 18% upside. Market really liked its write down on balance sheet or spinoff. Likes it here. Turned itself around. Will probably go to $80, and he'll evaluate it there.
insurance
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Sep 27/22, Up 22.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MET is progressing well. To remain disciplined, we now recommend trailing up the stop (from $52.50) to $62.00.
insurance
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly This world leader in insurance and benefits is a TOP PICK. The company just announced a deal along with PRU to assume the $16 billion pension obligation of IBM -- right up its alley. We like the value here as the company is trading under book value, just beat analyst earnings expectations, and is projected to trade 7x earnings. It has managed to increase cash reserves, while aggressively retiring debt and buying back shares. Its dividend is backed by a payout ratio under 50% of cash flow. We recommend placing a stop loss at $52.50, looking to achieve $77 -- upside potential of 25%. Yield 3.2% (Analysts’ price target is $77.25)
insurance
BUY
The insurers have been in fire, like MetLife. He believes rates will go higher, so definitely stick with them.
insurance
DON'T BUY
It's fine, but he does not likes financials (or energy). He just likes MET's yield and that's it.
insurance
COMMENT

AIG-N vs. MET-N. AIG-N has been recapitalizing since the disaster of the financial crisis. MET-N did not suffer these issues. The life business is in pretty decent shape but he prefers Canadian lifecos. (Analysts’ price target is $55.57)

insurance
BUY
It’s pretty cheap, trading at 8.1 times. Their earnings in July were double year over year and beat expectations. They are growing globally and it’s a safe name with a low valuation. Couldn’t go wrong with this choice in the long term.
insurance
WAIT
MET vs. BAC. Dynamics of the two are different, so hard to compare. FMV potential of both is huge. But the market won't go, because interest rates are falling. Aren't any drivers to escalate earnings. Very cheap, but who knows when they're going to pop? (Analysts’ price target is $53.19)
insurance
DON'T BUY
The balance sheet is impaired and there should be write-offs, which he hasn't seen. He sees 32% upside with a $64 model price, but he'd be happy seeing this at $53.80. He would recommend this stock above this price. He has recommended MET before, but MET just can't get going. The balance sheet is ugly. Also, if interest rates fall to zero, all insurance companies will get hit.
insurance
PAST TOP PICK
(A Top Pick Mar 29/18, Up 3%) Slow or flar growth this and next year, but they are buying back stock. He sees 9% EPS growth this year. Their US retirement portfolio has been doing well. It's cheap at 8x PE and paying almost a 4% dividend. It's been stagnant for many years, but it has tailwinds of lower taxes and volume growth. They're growing in Asia and Europe.
insurance
DON'T BUY
Metlife vs. Prudential vs US banks Both are high quality and international. Strong. He doesn't love lifecos now, because there's a lot going on in health, such as the prevalance of diabetes. He wants to see higher interest rates which can benefit lifecos. As for banks, he'd stay away. The rates and yield curve have flattened. Met are doing the right thing, like a nice dividend and a big share buybacks. It isn't expensive and doing 10% earnings growth, but there are greener pastures elsewhere.
insurance
COMMENT
Insurance companies are trading below their lower benchmarks -- making him think there are issues with their balance sheets especially in a deflationary recession environment. This could lead to lower short term rates, which could impair their earnings. He would be cautious going forward for all insurance companies.
insurance
DON'T BUY
SLF-T vs. MET-N. He prefers Sunlife (SLF-T). It is higher quality and more defensive. Also they are down with the sector. There is more competition in the US vs. Canada.
insurance
Showing 1 to 15 of 108 entries

Metlife(MET-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 4

Stockchase rating for Metlife is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Metlife(MET-N) Frequently Asked Questions

What is Metlife stock symbol?

Metlife is a American stock, trading under the symbol MET-N on the New York Stock Exchange (MET). It is usually referred to as NYSE:MET or MET-N

Is Metlife a buy or a sell?

In the last year, 4 stock analysts published opinions about MET-N. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Metlife.

Is Metlife a good investment or a top pick?

Metlife was recommended as a Top Pick by on . Read the latest stock experts ratings for Metlife.

Why is Metlife stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Metlife worth watching?

4 stock analysts on Stockchase covered Metlife In the last year. It is a trending stock that is worth watching.

What is Metlife stock price?

On 2022-11-22, Metlife (MET-N) stock closed at a price of $76.92.